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Abstract: An environmental risk assessment is presented for mycophenolic acid (MPA), an immunosuppressive pharma-
ceutical used for prevention of organ rejection, and its prodrug mycophenolate mofetil (MPM). Mycophenolic acid will not
signiﬁcantly adsorb to activated sludge. In activated sludge, 14C‐MPA attained >80% degradation, supporting an older
environmental fate test with the same compound. Based on n‐octanol/water distribution coefﬁcient (log DOW) values of 2.28,
0.48, and ≤–1.54 at pH 5, 7, and 9, respectively, MPA is not expected to bioaccumulate. Sales amounts of MPA+MPM in
Europe were used to derive predicted environmental concentrations (PECs) in surface waters; PECs were reﬁned by including
expected biodegradation in sewage treatment, average drinking water use, and average dilution of the efﬂuents in the
receiving waters per country. In addition, the exposure to pharmaceuticals in the environment (ePiE) model was run for 4
European catchments. The PECs were complemented with 110 measured environmental concentrations (MECs), ranging
from below the limit of quantitation (<0.001 µg/L) to 0.656 µg/L. Predicted no‐effect concentrations (PNECs) were derived
from chronic tests with cyanobacteria, green algae, daphnids, and ﬁsh. The comparison of PECs and MECs with the PNECs
resulted in a differentiated environmental risk assessment in which the risk ratio of PEC/PNEC or MEC/PNEC was <1 in most
cases (mostly >90%), meaning no signiﬁcant risk, but a potential risk to aquatic organisms in generally <10% of instances.
Because this assessment reveals a partial risk, the following questions must be asked: How much risk is acceptable? and
Through which measures can this risk be reduced? These questions are all the more important in view of limited alternatives
for MPM and MPA and the serious consequences of not using them. Environ Toxicol Chem 2019;38:2259–2278. © 2019 The
Authors. Environmental Toxicology and Chemistry published by Wiley Periodicals, Inc. on behalf of SETAC.
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INTRODUCTION
Pharmaceuticals in the environment have gained increasing
scientiﬁc and regulatory attention over the past 30+ yr (Straub and
Hutchinson 2014; Kümmerer 2016). Detections, mainly in aquatic
environmental media, have multiplied with the recent massive
development of analytical technology. The biological potency of
active pharmaceutical ingredients (APIs) has led to the assumption
that residues may cause adverse effects in environmental organ-
isms. Regulatory requirements for environmental risk assessments
for APIs have been introduced and developed further in the United
States (Center for Drug Evaluation and Research 1998) and the
European Union (Straub and Hutchinson 2014), and regulations are
expected in the near future in Japan (Japanese Ministry of Health,
Labor, and Welfare 2016) and Canada (J. Chateauvert, personal
communication). One particular issue regarding pharmaceuticals in
the environment concerns those APIs that have carcinogenic,
mutagenic, or reprotoxic properties in laboratory mammals, due to
the suspicion of comparable adverse effects in environmental or-
ganisms (Committee for Medicinal Products for Human Use 2015).
The present study is an environmental risk assessment for an API
with such carcinogenic, mutagenic, or reprotoxic properties, my-
cophenolic acid (MPA), which has gathered attention in various
prioritization lists for pharmaceuticals in the environment (Roos
et al. 2012; Daouk et al. 2015; Guo et al. 2015; Aubakirova et al.
2017; Santos et al. 2017a).
Mycophenolic acid is 6‐(1,3‐dihydro‐4‐hydroxy‐6‐methoxy‐
7‐methyl‐3‐oxo‐5‐isobenzofuranyl)‐4‐methyl‐4‐hexenoic acid, a
small molecule with a molecular weight of 320.34 g/mol (CAS
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no. 24280–93–1; Roche 2017a; Figure 1). It was discovered
>100 yr ago as a natural substance synthesized by various
molds of the genus Penicillium (Anderson et al. 1988; cited in
Noto et al. 1969; Lee et al. 1990). It was recognized early to
potentially be a broad‐spectrum API, due to antibacterial, an-
tiviral, antifungal, antipsoriatic, and anticancer activity (the
latter through inhibition of angiogenesis; Florey et al. 1946;
Cline et al. 1969; Noto et al. 1969; Lee et al. 1990; Silverman
et al. 1997; Wu et al. 2006). It was also shown to be a speciﬁc
inhibitor of the immune system and was developed in the early
1990s as an immunosuppressant API used for the prevention of
solid organ rejection in transplant recipients (Fulton and
Markham 1996).
Mycophenolic acid is a reversible, potent, and noncompetitive
inhibitor of the enzyme inosine‐5′‐monophosphate de-
hydrogenase (IMPDH), which is essential for the biosynthesis of
purines (Wishart et al. 2018; Royal Pharmaceutical Society 2018).
Inhibition of IMPDH particularly affects lymphocytes because they
rely almost exclusively on de novo purine synthesis, whereas
many other cell types can switch to salvaging pathways (Wishart
et al. 2018; Royal Pharmaceutical Society 2018). Therefore, MPA
suppresses the proliferation of T‐ and B‐lymphocytes and also
inhibits antibody formation by B‐lymphocytes (Wishart et al.
2018). This selectivity for lymphocytes explains the off‐label use
of MPA in autoimmune diseases. The broad spectrum of activity
of MPA (just described) suggests that IMDPH occurs in all
eukaryotes (Gunnarsson 2008; Santos et al. 2017b), which is
supported by the ECOdrug database (Verbruggen et al. 2017),
and also in prokaryotes, in which IMPDH inhibition by MPA seems
to be weaker (Digits and Hedstrom 1999; Gunnarsson 2008).
In view of its relatively low oral bioavailability, MPA was
derivatized by Syntex (now integrated into F.Hoffmann‐La Roche
[Roche]) in the early 1990s to the prodrug mycophenolate mo-
fetil (MPM; CAS no. 128794–94–5, 433.5 g/mol; Figure 1; Roche
2017b), the morpholinoethyl ester of MPA (Lee et al. 1990;
Fulton and Markham 1996). Mycophenolate mofetil has 1.3 to
2.36 times higher oral bioavailability than MPA and is rapidly and
fully hydrolyzed to MPA in the liver and intestine (Lee et al. 1990;
Shipkova et al. 2005). Thus, pharmacologically active MPA levels
are reached subsequent to MPM dosage of three‐quarters to
less than one‐half of the corresponding amount of MPA.
Due to its mode of action, MPA is also mutagenic and
teratogenic in mammals; hence, based on data from the Com-
mittee for Medicinal Products for Human Use (2015), concerns
exist over persistence, bioaccumulation, or speciﬁcally high
ecotoxicity properties of MPA in the environment. Some funda-
mental environmental data were developed by Syntex at the
time of clinical development of MPA and MPM, but no chronic
ecotoxicity tests or other basic environmental risk assessment
data that are considered crucial today (Committee for Medicinal
Products for Human Use 2015). Additional tests were commis-
sioned by Roche to allow an updated environmental risk as-
sessment for European surface waters that considers both the
potential persistence, bioaccumulation, or high ecotoxicity
properties and the total actual use of MPM and MPA; the present
study describes the resulting environmental risk assessment.
MATERIALS AND METHODS
Existing tests, databases, and literature data
Roche internal databases, the European Chemicals Agency
(2018) database, and the scientiﬁc literature were searched for
physicochemical, toxicological, and environmentally relevant
data as well as measured environmental concentrations (MECs)
for MPM and MPA. In addition, the IQVIA MIDAS Quantum
subscription database (IQVIA 2018) was queried for sales
amounts in kilograms of MPM and MPA in European countries
for the period 2004 to 2017, with the aim of basing the envi-
ronmental risk assessment on realistic use data.
The existing Syntex tests comprise the following internal,
non–good–laboratory–practice (GLP) tests and external, GLP‐
compliant studies: vapor pressure of MPA; photodegradation of
MPA in aqueous solutions; and biodegradability of 14C‐labeled
MPM (2 test substances with radiolabels in different moieties of
the molecule) in river water and sediment. Descriptions of the
test methods applied are given in the Supplemental Data. Ad-
ditional tests following Organisation for Economic Co‐operation
and Development (OECD; 2018) test guidelines in compliance
with GLP, ensuring the validity of the procedures and statistics
(Caldwell et al. 2018), were commissioned by Roche. Because
MPM is fully cleft to MPA and the excreted metabolites
are 7‐O‐MPA glucuronide (MPAG) and MPA, all new tests were
performed with the active moiety MPA. The following tests were
performed: OECD test guideline 106 phase I batch equilibrium
adsorption test (Organisation for Economic Co‐operation and
Development 2000); OECD test guideline 314B activated
sludge biodegradation simulation test (Organisation for Eco-
nomic Co‐operation and Development 2008); OECD test
guideline 201 algal growth inhibition test with Anabaena ﬂos‐
aquae (cyanobacteria; Organisation for Economic Co‐operation
and Development 2011); OECD test guideline 211 chronic re-
production test with Daphnia magna (Organisation for Economic
Co‐operation and Development 2012); and a ﬁsh partial life
cycle test consisting of an OECD test guideline 229 short‐term
reproduction test (Organisation for Economic Co‐operation and
Development 2012b) followed by an OECD test guideline 210
early life stage test with Danio rerio (Organisation for Economic
Co‐operation and Development 2013). Also, a ready bio-
degradability study according to OECD test guideline 301F was
performed with MPM (Organisation for Economic Co‐operation
and Development 1992). Descriptions of the test methods
applied are given in the Supplemental Data.
© 2019 The Authors wileyonlinelibrary.com/ETC
FIGURE 1: Structure of mycophenolate mofetil (whole molecule),
mycophenolic acid (moiety to the left of broken line), and morpholi-
noethanol (mofetil; moiety to the right of broken line).
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Predicted and measured environmental
concentrations
For 24 documented European countries, the administered
amount of MPA and the stoichiometric fraction of MPA from
MPM administration in kg/yr were retrieved for the period 2004
to 2017 (IQVIA 2018), for the derivation of predicted environ-
mental concentrations (PECs). For each combination of country
and year, these amounts were summed and divided by the
population in that country and year (European Commission
2018), and by 365 d, to derive year‐speciﬁc daily per capita
uses. In addition to single‐country uses, we also derived year‐
speciﬁc European uses as the average daily per capita use over
all countries.
An initial MPA sewage treatment plant (STP) PEC following
the European Medicines Agency (EMA) guideline (Committee
for Medicinal Products for Human Use 2015) was obtained by
dividing the highest overall European MPA daily per capita use
by a default 200 L of wastewater/inhabitant/day; no human me-
tabolism or removal in STPs was included. When the EMA
guideline default dilution factor was applied, the initial surface
water PEC was 10 times lower (Committee for Medicinal Prod-
ucts for Human Use 2015). (Note that this default has been
contested for single German rivers by Link et al. [2017]. On the
other hand, data by Keller et al. [2014] suggest that the average
and median dilution factors for European countries are >10,
whereas Belgium, for example, has a lower dilution.) Reﬁned
MPA STP PECs per country were calculated by dividing the
highest country‐speciﬁc daily per capita MPA use by the country‐
speciﬁc daily water use (Keller et al. 2014). Reﬁned MPA surface
water PECs per country were then determined by deducting a
predicted STP removal based on the OECD test guideline 314B
(Organisation for Economic Co‐operation and Development
2008) test results using SimpleTreat 4.0 model (Struijs 2015) for
80% of MPA mass (no wastewater treatment was assumed for the
remaining 20%) and further division by the median country‐
speciﬁc dilution factor (Keller et al. 2014). For comparison with
the initial PECs based on the EMA guideline, average European
reﬁned, population‐, water‐use‐, and dilution‐factor–weighted
PECs for STPs and receiving waters were calculated as well.
The geographically based exposure to pharmaceuticals in
the environment (ePiE; Oldenkamp et al. 2018) model was ap-
plied to derive distributions of PECs in European river catch-
ments. The ePiE model was developed within the research
project intelligence‐led assessment of pharmaceuticals in the
environment (iPiE 2019) and combines high‐resolution geore-
ferenced information on river ﬂow and locations of STPs with
information on number of inhabitants attached, API con-
sumption, human metabolism, and fate of APIs during their
passage through STPs and receiving surface waters. The model
was run under annual mean, maximum, and minimum monthly
ﬂow conditions for the year 2015, and was applied to 4
climatically and hydrologically diverse river basins: the Rhine
catchment, with a total population of approximately 58 million
in 2009 (Uehlinger et al. 2009), receiving water and efﬂuents
from Switzerland, Liechtenstein, Austria, France, Germany,
Luxembourg, Belgium, and The Netherlands; the Ouse Basin in
northern England, UK; and the Turia and Guadalquivir catch-
ments, in eastern and southern Spain. Average total MPA use
data for these countries (except Liechtenstein, for which no
separate use data are available) were entered into ePiE, as were
physicochemical and environmental fate data, to derive catch-
ment‐wide PECs reﬂecting the geographical distributions of the
modeled concentrations. We regarded the Rhine catchment as
representative of climatically moderate northwestern Europe,
with a signiﬁcant share of >10% of the total European pop-
ulation (Uehlinger et al. 2009; European Commission 2018). The
2 Spanish catchments are representative of warmer and drier
southern Europe; the Guadalquivir is a basin near the large cities
of Cordoba and Seville, with a correspondingly high population/
STP efﬂuent contribution; the Turia catchment is smaller and
more agriculturally inﬂuenced. Finally, the Ouse catchment is
regarded as representative for more Atlantic‐inﬂuenced western
Europe.
The MECs for MPA were searched for in the scientiﬁc liter-
ature using the terms “mycophenol*”, “environment*”, and
“concentration”, collated and percentage‐ranked following
Straub (2008).
Predicted no‐effect concentrations
The predicted no‐effect concentration (PNEC) for STPs
(PNECSTP) was derived by dividing the lowest activated sludge
respiration inhibition no‐observed‐effect concentration (NOEC)
by an assessment factor of 10. The surface (fresh) water
PNECSW was derived in 2 ways, from the lowest chronic NOEC
on the one hand and from the lowest chronic 10% effect con-
centration (EC10) on the other, from (sub)chronic tests with ﬁsh,
daphnids, green algae, and cyanobacteria (for the latter 2 the
NOErC/ErC10 for growth rate [r] was used), using an assess-
ment factor of 10 (Committee for Medicinal Products for
Human Use 2015).
Risk assessment
The potential risk for STPs and surface freshwater organisms
was characterized by dividing the various PECs and MECs by
the respective PNECs for MPA (Committee for Medicinal
Products for Human Use 2015). Further risk assessments were
performed for antibiotic resistance risk due to the described
antibiotic activity of MPA, risk for environmental top predators,
and also risk for humans through so‐called secondary poi-
soning from uptake of water or ﬁsh.
Antibiotic resistance risk is assessed through comparing PECs
or MECs with a PNEC for formation or maintenance of antibiotic
resistance (PNECABR). There is no universally accepted or regu-
latory algorithm for deriving a reliable PNECABR for bacteria,
so for the time being this is approximated by applying assess-
ment factors to bacterial minimal inhibitory concentrations
(MICs). Kümmerer and Henninger (2003) applied an assessment
factor of 100 to the lowest bacterial MIC/antibiotic. In 2016,
Bengtsson‐Palme and Larsson used the lower 1st percentile
(%ile) MIC/antibiotic and applied 2 assessment factors, a general
wileyonlinelibrary.com/ETC © 2019 The Authors
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factor of 10, and an additional factor that depends on the size of
the MIC dataset and reﬂects the magnitude of uncertainty. To
be fully consistent with Bengtsson‐Palme and Larsson’s (2016)
approach to PNECABR derivation, the authors were contacted for
help; they (J. Bengtsson‐Palme, Department of Infectious Dis-
eases, Institute of Biomedicine, The Sahlgrenska Academy,
University of Gothenberg, Gothenberg, Sweden, personal
communication) state that “we only use species with 10 or more
MIC observations, to avoid drawing conclusions from insufﬁcient
data [...]. The only species with >10 observations in the Noto
et al. (1969) paper is S[taphylococcus] aureus. In addition, when
the MIC1% are selected, only one MIC [J.O.Straub’s italics] value
is selected per species (the lowest). Finally, the uncertainty factor
for low sampling numbers is calculated as: (observed lowest
MIC) × (number of tested species) ÷ 41.” Both these provisional
PNECABR values were derived from the MPA MICs; the lower
was selected and compared with the PECs and MECs.
The potential risk for (semi)aquatic top predators such as otters
that consume ﬁsh and drink surface water was assessed by
maximum tolerable daily intake (MTDI) calculated following
Murray‐Smith et al. (2012) and the European Union technical
guidance for deriving environmental quality standards (European
Commission 2011). In brief, acute and long‐term mammalian
toxicity results are divided by appropriate assessment factors,
depending on the nature and duration of the tests, to derive an
MTDI. For an otter, a default body mass of 10 kg, an intake of
1 kg ﬁsh, and 0.79 L of water/d is assumed; the concentration of
the substance in ﬁsh results from the surface water PEC and the
bioconcentration factor (BCF). The combined daily intake from
ﬁsh and water is then compared with the MTDI (Murray‐Smith
et al. 2012).
Similarly, potential risk for humans from secondary poisoning
is assessed by using the acceptable daily exposure (ADE) value
for MPA (T. Pﬁster, unpublished data), which considers toxico-
logical data as well as human experience and covers all routes of
uptake, including sensitive subpopulations, over 365 d/annum,
with the combined worst‐case uptake through drinking water
and ﬁsh. No removal of MPA in drinking water production is
assumed, but a default intake of 2 L water and 115 g ﬁsh/person
and day is assumed (European Commission 2011; Murray‐Smith
et al. 2012). This combined uptake is then compared with
the ADE.
RESULTS AND THEIR CONTEXT
Physicochemical properties and
environmental fate
Syntex derived many basic physicochemical properties for both
MPM and MPA in the early 1990s. The results for MPA are mostly
given in the present study. Syntex internal tests were performed
without GLP compliance, but with full documentation (protocol,
experimental data, analytics with validation, and calculation algo-
rithms included in reports): solubility in buffered aqueous
solutions, dissociation constant (pKa) determined by titration,
screening vapor pressure, n‐octanol/water distribution coefﬁcient
(log DOW) by the shake‐ﬂask method, and screening hydrolysis
(Table 1; T.J. Lynch and N. Licato, Syntex, Palo Alto, CA, USA/
F.Hoffmann‐La Roche, Basle, Switzerland, unpublished data; V.
Nicholson, Syntex, Palo Alto, CA, USA/F.Hoffmann‐La Roche,
Basle, Switzerland, unpublished data; V. Nicholson and N. Licato,
Syntex, Palo Alto, CA, USA/F.Hoffmann‐La Roche, Basle, Switzer-
land, unpublished data; V. Nicholson et al., Syntex, Palo Alto, CA,
USA/F.Hoffmann‐La Roche, Basle, Switzerland, unpublished data;
A. Young and N. Licato, Syntex, Palo Alto, CA, USA/F.Hoffmann‐La
Roche, Basle, Switzerland, unpublished data).
The logDOW values ≤2.28 at pH 5 to 9 (A. Young and N. Licato,
unpublished data) suggest that MPA will not bioaccumulate sig-
niﬁcantly. Because no experimental bioaccumulation data have
been located, quantitative structure–property (QSPR) models were
used to estimate BCFs for MPA. The EPISuite Ver 4.11 software
calculates a BCF (wet wt) for ﬁsh of 3.16, independent of ionization
(US Environmental Protection Agency 2016). The SciFinder data-
base models BCFs along most of the pH range, with the highest
value of 486 at pH 1, which drops to 161 at pH 5, to 23.2 at pH 6,
© 2019 The Authors wileyonlinelibrary.com/ETC
TABLE 1: Physicochemical data for mycophenolic acida
Property Value Unit Condition Reference
Solubility in water 45 mg/L pH 5, 25 ± 2 °C T.J. Lynch and N. Licato, Syntex, Palo Alto, CA, USA/
F.Hoffmann‐La Roche, Basle, Switzerland, unpublished data.
710 mg/L pH 7, 25 ± 2 °C T.J. Lynch and N. Licato, unpublished data.
pKa, carboxylic acid 4.58 — 25 ± 2 °C T.J. Lynch and N. Licato, unpublished data.
pKa, phenolic 8.045 — 25 ± 2 °C V. Nicholson and N. Licato, Syntex, Palo Alto, CA, USA/
F.Hoffmann‐La Roche, Basle, Switzerland, unpublished data.
Vapor pressure 3.2 × 10–7 Torr V. Nicholson et al., Syntex, Palo Alto, CA, USA/F.Hoffmann‐
La Roche, Basle, Switzerland, unpublished data.
= 4.27–7 hPa V. Nicholson et al., unpublished data.
Log DOW 2.28 — pH 5 A. Young and N. Licato, Syntex, Palo Alto, CA, USA/
F.Hoffmann‐La Roche, Basle, Switzerland, unpublished data.
0.48 — pH 7 A. Young and N. Licato, unpublished data.
≤–1.54 — pH 9 A. Young and N. Licato, unpublished data.
Screening hydrolysis 46.15 % Substance loss pH 5, 50 °C, 5 d A. Young and N. Licato, unpublished data.
29.03 % Substance loss pH 7, 50 °C, 5 d A. Young and N. Licato, unpublished data.
36.67 % Substance loss pH 9, 50 °C, 5 d A. Young and N. Licato, unpublished data.
aBased on tests by Syntex. Test procedures are described in the Supplemental Data.
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to 2.49 at pH 7, and to 1.0 at pH 8 to 10 (American Chemical
Society 2018), echoing the log DOW distribution
(Table 1). The geometric average of the SciFinder values in the
environmentally relevant range of pH 5 to 9 is a BCF of 6.22.
These models support the log DOW‐based prediction of no sig-
niﬁcant bioaccumulation for MPA.
The low vapor pressure of <10–6 hPa (V. Nicholson and N.
Licato, unpublished data) suggests that MPA will not volatilize to a
signiﬁcant extent. The screening hydrolysis test resulted in 29.03
to 46.15% substance loss at pH 5 to 9 (A. Young and N. Licato,
unpublished data). These losses suggest that under environ-
mental conditions (default 12 °C water temperature in Europe)
there will only be slow hydrolysis. In conﬁrmation, Franquet‐Griell
et al. (2017a) recently reported a hydrolytic degradation constant
for MPA of 0.0002 min–1.
The photodegradation test shows kphoto values at pH 5
ranging from 0.0017 min–1 in winter to 0.0059 min–1 in summer,
at pH 7 from 0.0049 min–1 to 0.018 min–1 and at pH 9 from
0.0087 min–1 to 0.031 min–1 (V. Nicholson, unpublished data).
Marín‐García (2015) studied ultraviolet (UV)‐C photodegradation
of MPA; at pH 7, 20 mg/L MPA showed negligible photo-
degradation but higher rates at pH 10 to 12 (Marín‐Garcia 2015),
suggesting that very‐short‐wave UV‐C does not signiﬁcantly de-
grade MPA at environmentally relevant pH levels. In contrast,
Franquet‐Griell et al. (2017a) reported MPA kphoto values of
0.0284 min–1 for UV‐C irradiation and 0.004 min–1 in a Solar Box
artiﬁcial sunlight reactor. The former rate suggests relatively rapid
degradation under UV‐C exposure, whereas the latter rate
compares rather well with the data just given above developed
under natural sunlight by V. Nicholson (unpublished data).
Giebułtowicz and Nałec̨z‐Jawecki (2016) presented a UV‐visual
light spectrum of MPA in their Supporting Information with a λmax
at 215 nm and 2 sequentially lower peaks at 248 and 297 nm,
conﬁrming UV‐C photosensitivity. Altogether, these data suggest
a notable removal of MPA in surface waters through photo-
degradation, which, however, is strongly dependent on season,
latitude, water depth, turbidity, and pH level.
The sediment/water fate test (Z. Yan, ABC Laboratories,
Columbia MO, USA, on behalf of Syntex, Palo Alto, CA, USA/
F.Hoffmann‐La Roche, Basle, Switzerland, unpublished data)
shows that the overall 14C mass balance for all systems and
concentrations was satisfactory, with a minimum of 90.4 ± 0.9%
and a maximum of 99.9 ± 5.6%. At the end of the test, in the
carboxyl‐14C‐labeled MPM systems, 58.9 and 60.2% (for 1 and
5 mg/L dosing, respectively) of applied 14C activity was trapped
as 14CO2, whereas 4.8 and 6.7% remained in water and 17.6 and
20.3% was bound to sediment, plus some activity found in the
samples for analyses. In the morpholine‐14C–labeled MPM sys-
tems, 21.5 and 28.0% was trapped as 14CO2, whereas 41.5 and
32.4% remained in the water and 12.0 and 12.4% was bound to
sediment, plus the samples activity. The analysis of 14CO2 and
high‐performance liquid chromatography (HPLC) data showed
that full primary degradation took place in all systems and dos-
ings within 7 d, resulting in several transformation products. The
transformation products were further biodegraded, partially
mineralized, or bound to sediment during the 64‐d test period.
HPLC cochromatography of day 64 samples with the respective
14C reference standards showed that both forms of 14
C‐labelled MPM had completely disappeared, leaving no sig-
niﬁcant peak at all in the carboxyl‐14C‐MPM systems and a small
peak of an unidentiﬁed transformation product in the morpho-
line‐14C‐MPM systems. This particular transformation product was
shown by HPLC to reach a peak of approximately 75 to 85%
relative to initially applied by day 7 and then to decrease to 40 to
50% in the morpholine‐14C‐MPM systems, and to 5 to 10% in the
carboxyl‐14C‐MPM systems. The report states, “Compared to the
morpholine‐14C radiolabeled metabolite, the carboxyl‐14C ra-
diolabeled metabolite (probably 14C‐mycophenolic acid) is much
more easily biodegraded and mineralized” (Z. Yan, unpublished
data, p 23). This sediment/water fate test shows that the parent
MPM is lost from the systems with a 50% disappearance time
(DT50) of <2 d in all cases. The carboxyl‐14C‐MPM transformation
product, tentatively identiﬁed by the authors as 14C‐MPA, is
nearly completely degraded by the end of the test, with a DT50
of approximately 14 d. The unidentiﬁed morpholine‐14C‐MPM
transformation product is degraded much more slowly, but on
day 64 this transformation product, the only peak remaining, had
a much smaller area (no quantitative data available) on the
chromatogram, compared with the reference standard. Alto-
gether, this test suggests that MPM is transformed rapidly in
natural river water/sediment systems, and may in part form non-
extractable, bound sediment residues while the remainder in the
aqueous phase is partially to nearly fully mineralized.
Franquet‐Griell et al. (2017a) also investigated the bio-
degradation of MPA in an aerobic sequencing batch reactor with
an initial concentration of 1 to 1.2 g/L activated sludge that was
run for 5 cycles of 48 h each, after which the activated sludge
was left to settle, the supernatant was decanted, and each cycle
was supplied with fresh primary efﬂuent spiked with the same
MPA concentration. While in the ﬁrst cycle, approximately 58%
of MPA was still detected after 48 h; in the ﬁfth cycle, no MPA at
all was detected already after 24 h, showing the adaptation of
the biomass to degrade MPA. Franquet‐Griell et al. (2017a)
calculated biodegradation rate constants kbiodeg for MPA in the
ﬁrst cycle of 0.0017 min–1 and in the ﬁfth cycle of 0.006 min–1,
speciﬁcally remarking about the “degradation capacity of
aerobic activated sludge for [this] compound.”
The new adsorption test following OECD test guideline 106
(Organisation for Economic Co‐operation and Development
2000) showed satisfactory mass balances between 95 and
107%; based on pretests, MPA was shown by analytics to be
stable over the selected equilibration time of 10 h (recoveries
from 0.01 M CaCl2 after 24 h: 104% at 0.2 mg MPA/L and 97%
at 20 mg MPA/L). The main test resulted in soil Kd values of 2.2,
2.8, and 5.0 L/kg and activated sludge Kd values of 9.3 and 13
L/kg; normalizing to organic carbon content, the highest KOC
for MPA was 37 L/kg in one of the activated sludges (V. Halász‐
Laky, Toxi‐Coop ZRT, Balatonfüred, Hungary, on behalf of
F.Hoffmann‐La Roche, Basle, Switzerland, unpublished data).
Hence, MPA does not sorb signiﬁcantly to activated sludge in
STPs, but is mobile and remains in the aqueous phase (Briggs
1973; McCall et al. 1980). Thus, MPA is not expected to be
signiﬁcantly transferred to soil with surplus sludge
(Committee for Medicinal Products for Human Use 2015).
wileyonlinelibrary.com/ETC © 2019 The Authors
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An OECD test guideline 301F (Organisation for Economic Co‐
operation and Development 1992) ready biodegradability test
with MPM at a nominal concentration of 100 mg/L (A. Häner,
unpublished data) showed primary degradation by HPLC without
oxygen uptake, which was interpreted as hydrolysis of the mofetil
ester without subsequent biodegradation of both moieties.
The new OECD test guideline 314B (Organisation for Eco-
nomic Co‐operation and Development 2008) activated sludge
degradation test (T. Junker and M. Herrchen, ECT Oekotox-
ikologie, Flörsheim, Germany, on behalf of F.Hoffmann‐La
Roche, Basle, Switzerland, unpublished data) fulﬁlled all
quality and validity criteria (see the Supplemental Data). The
test item was rapidly mineralized, with biodegradation starting
directly after application, and increasing rapidly at the begin-
ning and more slowly afterward up to 82.2% of initially re-
covered radioactivity (iRR) at day 28 (Figure 2). Mineralization
comprises evolved CO2 (detected in the traps) as well as CO2
dissolved in the sludge. The latter was highest at day 2 and
decreased afterward, whereas the amount of evolved CO2
increased continuously until the end of the study. At the start
of the test (day 0), 82.5% iRR was detected in the liquor ex-
tracts; the liquor extract radioactivity decreased to 1.2% iRR at
the end of the test. At no time point was a noteworthy amount
of radioactivity (>2% iRR throughout the test period) detected
in the liquor after extraction. Radioactivity in the solids extract
was highest at day 0 (5.5% iRR) and decreased afterward to
0.3% iRR after 28 d. Nonextractable residues increased at the
beginning up to 10.2% iRR on day 2, did not change sub-
stantially until day 14 (range: 11.1 to 13.1% iRR), and then fell
to 7.3% iRR on day 28.
Using the curve for total CO2 produced over time in this
OECD test guideline 314B (Organisation for Economic
Co‐operation and Development 2008) test (T. Junker and
M. Herrchen, unpublished data), a biodegradation rate con-
stant kbiodeg of 0.0174 h
–1 or 0.00029 min–1 can be calculated
for MPA in STPs. Based on this kbiodeg and physicochemical
properties for MPA, SimpleTreat 4.0 (Struijs 2015) calculated a
removal of 12% in STPs, mostly through biodegradation
(0.27% in the primary settler and 11.5% in the aeration tank),
with a small fraction of 0.13% adsorbed to sludge, in agree-
ment with the OECD test guideline106 (Organisation for
Economic Co‐operation and Development 2000) adsorption
results mentioned in the previous paragraph (V. Halász‐Laky,
unpublished data). However, when the kbiodeg data developed
by Franquet‐Griell et al. (2017a) were entered in the se-
quencing batch reactor for kbiodeg of 0.0017 min
–1 in the ﬁrst
cycle, SimpleTreat calculated a removal of 43.6% in STPs
(0.272% biodegradation primary settler, 43.24% aeration
tank; 0.080% adsorbed); for kbiodeg in the ﬁfth cycle of 0.006
min–1, SimpleTreat calculated a removal of 73.1% in STPs
(0.272% primary settler, 72.77% aeration tank; 0.0373% ad-
sorbed; Struijs 2015). A high degradation rate is supported by
data from Franquet‐Griell et al. (2017b), who measured STP
inﬂuents and efﬂuents and compared solid phase extraction
and macroporous ceramic passive samplers in Spain. The STP
in question treats 65% of the wastewaters from Barcelona and
surroundings (2 843 750 inhabitant equivalents) and receives
urban waters, efﬂuents from 3 large hospitals, and industrial
waters; the STP performs biological treatment without ni-
trogen and phosphorus removal. Based on substance con-
centrations in efﬂuent and inﬂuent, removal rates of >90%
emerged for MPA (Franquet‐Griell et al. 2017b).
As a further conﬁrmation of biodegradability during waste-
water treatment, weekly measurements of MPM and MPA con-
centrations in the inﬂuent and efﬂuent of a small industrial
activated sludge STP at a Roche production site were made
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FIGURE 2: Graph of Organisation for Economic Co‐operation (OECD) test guideline 314B activated sludge biodegradation test with [14C]‐
mycophenolic acid, ECT Oekotoxikologie on behalf of Roche (Junker T, Herrchen M. 2017. Mycophenolic acid, [carboxyl‐14C]: A study on the
biodegradation in activated sludge according to OECD guideline no. 314B: Simulation tests to assess the biodegradability of chemicals discharged
in wastewater—Biodegradation in activated sludge. ECT Oekotoxikologie, Flörsheim, Germany, on behalf of F.Hoffmann‐La Roche, Basle,
Switzerland, unpublished data). %IRR = percentage of initially recovered radioactivity; NER = nonextractable residues.
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during 8 wk of MPM production in 2008 (G. Cahill, F.Hoffmann‐La
Roche, Basle, Switzerland, internal memo dated 19 September
2008, unpublished Roche data). The removal was between 74
and 95% in 6 of these weeks, whereas in the 2 remaining wk there
was no signiﬁcant removal in one sample, but negative removal of
–73% in the other. The memo does not give any information as to
whether in the latter 2 wk, asynchronous sampling of inﬂuent and
efﬂuent may have led to no or negative removal, and the site has
stopped production in the meantime. Still, including all 8 meas-
urements, the average removal was 52% and the median removal
was 83%, which clearly supports efﬁcient biodegradation of MPM
and MPA in activated sludge STPs. Therefore, the 3 SimpleTreat
removal predictions in the previous paragraph were used for low,
middle, and high removal scenarios and derivation of the corre-
sponding reﬁned PECs.
Use data
Use data for MPM and MPA for the years 2004 to 2017 were
retrieved from the IQVIA (2018) MIDAS database for the fol-
lowing 24 European countries: Austria, Belgium, Bulgaria,
Croatia, the Czech Republic, Denmark, Finland, France,
Germany, Greece, Ireland, Italy, Latvia, Luxembourg, The
Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia,
Spain, Sweden, Switzerland, and the United Kingdom. For
Greece, Latvia, and Luxembourg, only retail data were avail-
able (i.e., no hospital use data); however, this is not regarded as
a major drawback, because MPM and MPA have to be taken on
a daily basis over an indeﬁnite time and therefore most of the
use amounts will be at home, not in hospitals. This assumption
is also supported by Franquet‐Griell et al. (2015, p 163). The 24
countries are estimated to comprise 504.7 million inhabitants in
2017, corresponding to approximately 93.4% of the total
western and middle European population of 540.3 million
(European Commission 2018). Therefore, the available data for
MPA are regarded as representative for Europe.
PECs and MECs
Because the single sales amounts are the intellectual prop-
erty of IQVIA, the original data may not be shared as such, but
only in processed form. The initial, overall‐use–based European
MPA PECs and the reﬁned average and single‐country highest‐
use–based MPA PECs for STPs and receiving freshwaters were
calculated as described in the Materials and Methods section.
The reﬁned PECs based on 3 different SimpleTreat removal
predictions and ePiE PECs for the Rhine and Guadalquivir
Rivers assuming only 12% STP removal are shown in Table 2.
For the reﬁned, country‐speciﬁc, water‐use‐ and dilution‐
factor–based PECs, note that the highest PECs for STPs and
receiving waters do not necessarily denote the same country,
because low average water use will result in a high STP PEC but
in case of subsequent high dilution this may still lead to a low
surface water PEC. For the initial– and reﬁned‐use–based PECs,
the STP PECs ranged from 0.898 to 8.830 µg MPA/L, and the
surface water PECs ranged from <0.001 to 0.532 µg MPA/L.
The median reﬁned European, population‐, water‐use‐, and
dilution‐factor–weighted surface water PECs for 12, 43.6, and
73.1% STP removal were 0.058, 0.042, and 0.027 µg MPA/L,
respectively. The ePiE distributions were calculated using all
stretches in the respective ePiE catchments, that is, they in-
cluded all those parts of rivers and tributaries upstream of the
uppermost STP, where 0 concentrations are predicted. Under
annual mean monthly ﬂow conditions, the ePiE surface water
PECs for the 4 catchments ranged from <0.001 to 5.495 µg
MPA/L. This maximum corresponds to the 99th %ile of the
Guadalquivir PECs, whereas the median Rhine and Gua-
dalquivir ePiE PECs were 0.007 and <0.001 µg MPA/L. Under
annual minimum monthly ﬂow conditions, the worst‐case ePiE
PECs were higher, with median PECs of 0.021 and <0.001 µg/L
for the Rhine and Guadalquivir, and 99th %ile PECs of 2.666
and 12.419 µg/L, respectively. The extreme low‐ﬂow ePiE PEC
for the Guadalquivir is due to a high seasonal variability in river
ﬂow conditions. The ePiE mean‐ﬂow surface water PECs for the
Turia and Ouse catchments (Table 2) ranged from <0.001 to
0.318 and <0.001 to 0.534 µg MPA/L, respectively, with the
median in both cases being <0.001 µg/L.
Franquet‐Griell et al. (2015) calculated an average STP ef-
ﬂuent PEC of 2.008 µg MPA/L and a surface water PEC of
0.0774 µg MPA/L, based on the total MPA use in Catalunya
over the last 3 yr before their publication, 41% removal in STPs,
and the country‐speciﬁc dilution factor for Spain from Keller
et al. (2014). In view of the uncertainties included (e.g., mod-
eled STP removal and the dilution factor, which encompasses
extremely dry regions in central and southern Spain), both of
these PECs correspond reasonably well with the ones derived
in the present study.
We only located a few surface water MECs for MPA, all
dating from recent years. In 2013, Rossi and Cheseaux re-
ported the presence of MPA in 3/3 samplings from the Swiss
Rhone River upstream of Lake Geneva, at 0.0014, 0.0015, and
0.0021 µg/L, with a limit of quantitation (LOQ) of 0.001 µg/L and
high uncertainty due to the low number of samples. Still, the 3
MECs, with an average of 0.0017 µg/L, correspond reasonably
well with the reﬁned use–based PEC for the whole of Switzer-
land assuming 73.1% STP removal of approximately 0.005 µg/L
(data not shown).
In 2016, Franquet‐Griell et al. (2016) published 9/9 MPA sur-
face water MECs for Spain, ranging from 0.0128 to 0.0562 µg/L
(mean: 0.0217 µg/L), in the lower, heavily industrialized and
urbanized River Llobregat in the south of Barcelona with a total
of nearly 5 million people, and followed it through drinking
water treatment to the ﬁnished water, where it was no longer
detected (0/2; LOQ of 0.0001 µg/L; Franquet‐Griell et al. 2016). In
the River Besòs in Catalunya, Spain, which runs through
“a heavily populated and industrialized area, receiving the au-
thorized discharges of 27 [STPs], 219 industries and 12 hospitals”
in northern Barcelona, Franquet‐Griell et al. (2017c) measured
cytostatic APIs. (Note that MPA is cytostatic only insofar as cell
growth that depends on purine biosynthesis without salvaging
pathways is inhibited, but not a cytostatic in the sense of classical
cell division inhibitors, even though it is included in Franquet‐
Griell et al. 2017c.) In 2 sampling campaigns in 2014, MPA was
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the target compound detected at the highest levels and was
present mainly in the lowest, most urbanized river stretches, in
7/19 samples at 0.0131 to 0.0895 µg/L (mean: 0.018 µg/L, with
nondetects counted as half the LOQ) in May and in 4/19 samples
at 0.0085 to 0.656 µg/L (mean: 0.0474 µg/L, with nondetects
counted as half LOQ) in July, with the latter, higher concen-
trations attributed by the authors to low water ﬂow in summer.
The dilution factor of the River Besòs is given as 1.2, showing
very low dilution and a high fraction of treated wastewater
(Franquet‐Griell et al. 2017c). The median combined MEC in
Catalunya is just below 0.001 µg/L in view of many nondetects in
the upper River Besòs, which is far lower than the reﬁned use–-
based PEC for the whole of Spain assuming 73.1% STP removal
of approximately 0.040 µg/L and lower again by another factor of
2 than the surface water PEC of 0.0774 µg MPA/L calculated by
Franquet‐Griell et al. (2015) themselves. The median MEC of just
below 0.001 µg/L is close to the median mean‐ﬂow ePiE PECs
for the Turia and Guadalquivir Rivers (both <0.001 µg/L), even
though these river catchments are situated in different parts
of Spain.
Giebułtowicz and Nałec̨z‐Jawecki (2016) measured MPA in 2
rivers in Poland, the smaller Utrata and the large Vistula, in both
cases upstream and downstream of STPs, in the Vistula down-
stream of the capital Warsaw, over 1 yr. They detected MPA 38/60
times in river water, from below an LOQ of 0.0005 to 0.180 µg/L
downstream of a large STP, and 0/9 times in ﬁnished drinking
water from the city of Warsaw. The median of Giebułtowicz
and Nałec̨z‐Jawecki’s (2016) surface water MECs, including the
nondetects, was close to 0.003 µg/L (mean: 0.0168 µg/L, with
nondetects counted as half LOQ), which is more than a factor of
10 lower than the reﬁned use–based PEC for Poland of just above
0.040 µg/L, assuming 73.1% STP removal.
A total of 110 published surface waters MECs for MPA have
been located to date, with 61 above the LOQ. These values,
including the nondetects, were compiled, back‐distributed, and
percentage‐ranked according to Straub (2008), resulting in a
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TABLE 2: Use‐based initial and reﬁned sewage treatment plant and surface freshwater European predicted environmental concentrations (PECs)
and measured environmental concentrations (MECs) for mycophenolic acid (MPA)
Environmental compartment
STP PEC or MEC Surface freshwaters PEC or MEC, ng/L, based on STP removal of
PECs or MECs µg/L Location 0% 12% 43.6% 73.1% NA
Average initial EMA EU PEC 2.990 Inﬂuent 0.299
Average reﬁned PEC per country 2.980 Inﬂuent 0.082 0.058 0.037
Median reﬁned PEC per country 2.960 Inﬂuent 0.058 0.042 0.027
Highest reﬁned PEC per country 8.830 Inﬂuent 0.532 0.383 0.245
Lowest reﬁned PEC per country 0.898 Inﬂuent 0.002b 0.001 <0.001
Rhine catchment mean ﬂow median ePiE PEC 0.007b
Rhine catchment mean ﬂow 99th percentile ePiE PEC 0.671b
Rhine catchment mean ﬂow 1st percentile ePiE PEC <0.001b
Rhine catchment low ﬂow median ePiE PEC 0.021b
Rhine catchment low ﬂow 99th percentile ePiE PEC 2.666b
Ouse catchment mean ﬂow median ePiE PEC 0.048b
Ouse catchment mean ﬂow 99th percentile ePiE PEC 0.711b
Ouse catchment mean ﬂow 1st percentile ePiE PEC 0.001b
Ouse catchment low ﬂow median ePiE PEC 0.195b
Ouse catchment low ﬂow 99th percentile ePiE PEC 2.881b
Turia catchment mean ﬂow median ePiE PEC 0.028b
Turia catchment mean ﬂow 99th percentile ePiE PEC 0.554b
Turia catchment mean ﬂow 1st percentile ePiE PEC <0.001b
Turia catchment low ﬂow median ePiE PEC 0.174b
Turia catchment low ﬂow 99th percentile ePiE PEC 4.959b
Guadalquivir catchment mean ﬂow median ePiE PEC <0.001b
Guadalquivir catchment mean ﬂow 99th percentile
ePiE PEC
5.495b
Guadalquivir catchment mean ﬂow 1st percentile
ePiE PEC
<0.001b
Guadalquivir catchment low ﬂow median ePiE PEC <0.001b
Guadalquivir catchment low ﬂow 99th percentile ePiE PEC 12.419b
Maximum MEC 4.190a Efﬂuent 0.656c
Realistic worst‐case (90th percentile) MEC ND 0.057d
Median MEC ~0.250a Efﬂuent ~0.002d
aHighest and median of 6 available STP efﬂuent MECs from Switzerland (Rossi and Cheseaux 2013).
bHighest surface water MEC from River Besòs, Catalunya, Spain (Franquet‐Griell et al. 2016, 2017c).
c90th percentile and median of 110 available surface water MECs from Switzerland, Spain, and Poland (based on Rossi and Cheseaux 2013; Franquet‐riell et al. 2016,
2017c; Giebułtowicz and Nałec̨z‐Jawecki 2016).
EMA EU PEC =MPA PEC based on overall European amounts of MPA and mycophenolate mofetil (MPM), no human metabolism beyond hydrolysis of MPM to MPA and
no STP removal included, default dilution factor of 10 (Committee for Medicinal Products for Human Use 2015); ePiE PEC = geographical information system–based
surface water PEC according to Oldenkamp et al. (2018); MEC = measured environmental concentration; PEC = predicted environmental concentration; MPA =
mycophenolic acid; MPM = mycophenolate mofetil; NA = no data available; ND = not determined due to low number of MECs; STP = sewage treatment plant.
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compound median MEC of just below 0.002 µg/L (75th %ile
~0.017 µg/L, 90th %ile ~0.057 µg/L, 95th %ile ~0.123 µg/L, 99th
%ile ~0.604 µg/L) and a maximum MEC of 0.656 µg MPA/L. The
overall mean, with nondetects counted as half the LOQ, was
0.022 µg/L. In view of the low number of MECs and the re-
striction to Switzerland, Poland, and northeastern Spain, it is
unknown whether these MECs and their distribution are repre-
sentative for Europe. The single comparisons with reﬁned PECs
per country given in the previous paragraph consistently suggest
an overestimation of the PECs by a factor of 3 for Switzerland, 13
for Poland, and 40 to 80 for Catalunya. The median MEC of
<0.002 µg/L for the Rhone River is reasonably close, however, to
the median mean‐ﬂow Rhine River ePiE PEC of 0.007 µg/L. The
overall distribution of MECs in comparison with the reﬁned and
ePiE PECs just described seems to support the notion of a too
conservative PEC derivation. However, the low total and pos-
sibly skewed distribution of MECs must be kept in mind before
accepting such conclusions as deﬁnitive.
Singer et al. (2016) identiﬁed and measured MPA in the
efﬂuent of 6 Swiss STPs, with an LOQ of 0.030 µg/L. They de-
tected MPA in all 6 efﬂuents with MECs of 0.065 to 4.190 µg/L
(median: 0.755 µg/L). Based on only 6 MECs, the range and
median compare reasonably well with the reﬁned use‐ and
water‐use–based STP PECs just described of 0.898 to 8.830
(median: 2.960) µg MPA/L.
Giebułtowicz and Nałec̨z‐Jawecki (2016) also detected MPA
“in very low concentrations [close to the limit of detection of
0.0015 µg/L] in sediment samples collected close to STPs.
However, [... they] concluded that the detected MPA is freely
dissolved in sediment porewater, which constituted approx-
imately 30% of sediment samples prior to freeze drying”
(Giebułtowicz and Nałec̨z‐Jawecki 2016, p 144). This likely
nonadsorption to sediment is in agreement with the new OECD
test guideline 106 (Organisation for Economic Co‐operation and
Development 2000; V. Halász‐Laky, Toxi‐Coop ZRT, Balatonf-
üred, Hungary, on behalf of F.Hoffmann‐La Roche, Basle, Swit-
zerland, unpublished data).
Drinking water treatment removes MPA to untraceable
concentrations (Franquet‐Griell et al. 2016; Giebułtowicz and
Nałec̨z‐Jawecki 2016). Giebułtowicz and Nałec̨z‐Jawecki (2016)
did not detect MPA in tap water in 9/9 samples in Poland.
Similarly, Franquet‐Griell et al. (2016) showed that MPA from
Llobregat River source water disappeared early in the drinking
water treatment process and was not detected in 2/2 ﬁnished
drinking water samples in Catalunya, Spain. Both groups had
LOQs of 0.001 µg/L for MPA.
Ecotoxicity
Syntex had MPA tested for acute daphnid ecotoxicity in
compliance with GLP according to US Food and Drug Admin-
istration guideline 4.08 (2006), a test that resulted in a 48‐h
median effect concentration (EC50) of 755 mg/L average
measured concentration (AMC) and a 48‐h NOEC of 440 mg/L
AMC (J.W. Blasberg and J. Bucksath, ABC Laboratories,
Columbia MO, USA, on behalf of Syntex, Palo Alto, CA, USA/
F.Hoffmann‐La Roche, Basle, Switzerland, unpublished data.).
The public European Union European Chemicals Agency
(2018) database gives a robust study summary for a static algal
growth inhibition test according to OECD test guideline 201
(Organisation for Economic Co‐operation and Development
2011) in compliance with GLP with MPA in green algae of the
species Rhaphidocelis (Pseudokirchneriella) subcapitata. The
algae were exposed to MPA concentrations ﬁrst for 24 h in
the dark, and then for 72 h under continuous illumination.
Analytical determinations of MPA concentrations were per-
formed at 0, 24, and 96 h. Due to decrease in MPA concen-
trations over time, the geometric mean measured
concentrations (GMMCs) for the 24‐ and 96‐h determinations
were calculated. The ErC50 for MPA was 68 µg/L, the ErC10
was 12 µg/L, and the NOErC was 9 µg/L (all GMMC; European
Chemicals Agency 2018). The Swedish FASS (2018) database
gives the following ecotoxicity information (endpoints only)
from Novartis for sodium‐MPA: the same algal data as above in
the Registration, Evaluation, Authorisation and Restriction of
Chemicals regulation, acute daphnid EC50 >100 mg/L in
D. magna (OECD test guideline 202; Organisation for
Economic Co‐operation and Development 1984) and acute
ﬁsh 50% lethal concentration (LC50) in Cyprinus carpio
of >100 mg/L (OECD test guideline 203; Organisation for
Economic Co‐operation and Development 1993); also, an
activated sludge respiration inhibition test according to OECD
test guideline 209 (Organisation for Economic Co‐operation
and Development 2010) resulted in a 3‐h EC50 of 2213 mg/L
and an EC10 of 69 mg/L (FASS 2018). Because the latter 3 tests
are from the same contract laboratory as the algal test above,
they were probably performed in compliance with GLP as well.
In addition, there is one older non‐GLP literature 16‐h LC50
value for the hypersaline water brine shrimp Artemia salina of
98.4 mg MPA/L (Ďuracǩová et al. 1977).
For terrestrial plant ecotoxicity, Wright (1951) examined the
phytotoxic effects of some antibiotics on germination and root
growth of wheat (Triticum sp.), white mustard (Sinapis alba),
and red clover (Trifolium pratense) on agar containing different
concentrations of test substances. The germination of mustard
and clover seeds, but not wheat seeds, was signiﬁcantly in-
hibited by MPA in a concentration‐dependent manner. How-
ever, MPA inhibited the root growth of all 3 plants with
increasing concentration. Although no statistics are given in the
publication, a concentration range of 1 to 5 ppm (1–5 mg/kg
agar) emerges as the lowest‐observed‐effect concentration
(LOEC) for both endpoints.
The new chronic ecotoxicity tests with cyanobacteria (D. Gilberg
and G. Chambers, ECT Oekotoxikologie, Flörsheim, Germany, on
behalf of F.Hoffmann‐La Roche, Basle, Switzerland, unpublished
data), daphnids (P. Egeler and J. Chambers, ECT Oekotoxikologie,
Flörsheim, Germany, on behalf of F.Hoffmann‐La Roche, Basle,
Switzerland, unpublished data), and ﬁsh (D. Gilberg and G.
Chambers, unpublished data) fulﬁlled the validity criteria of the
respective OECD guidelines (see the Supplemental Data). In the
new OECD test guideline 201 (Organisation for Economic
Co‐operation and Development 2011), exposure of the cyano-
bacterium A. ﬂos‐aquae resulted in a clear concentration–response
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relationship for both biological parameters growth rate and yield
during the exposure period. The following endpoints were de-
termined, all relating to GMMC: NOEC (both growth and yield)
83.9 µg MPA/L, LOEC 284 µg/L, ErC10 155 (95% conﬁdence in-
terval [CI] 137–171) µg/L, and ErC50 423 (95% CI 406–441) µg/L
(D. Gilberg and G. Chambers, unpublished data).
In the new OECD test guideline 211 (Organisation for
Economic Co‐operation and Development 2012a) reproduction
test with D. magna, a clear dose–response relationship was
found for fecundity and reproduction, with a NOEC of 630 µg
MPA/L, a LOEC of 1800 µg/L, and an EC10 of 929 µg/L (no 95%
CI possible), all GMMC. No clear dose–response relationship
was found for the endpoint length of parental daphnids (NOEC
630 µg/L, LOEC 1800 µg/L, both GMMC), nor for the 2 end-
points mortality/immobility of parental daphnids and intrinsic
rate of population increase, which both showed a NOEC at the
highest tested concentration of 7530 µg MPA/L GMMC and a
LOEC of >7530 µg/L (D. Gilberg and G. Chambers, unpublished
data). Thus, the overall NOEC for the daphnids is 630 µg MPA/L
and the overall EC10 is 929 µg/L, both GMMC.
In the ﬁsh partial life cycle test test with D. rerio, at the end of
the OECD test guideline 229 (Organisation for Economic
Co‐operation and Development (2012b) test phase at 23 d, no
concentration–response relationship was observed for the
parameters survival of the parental ﬁsh, fecundity, and fertilization
success for the F0 generation. The NOEC of all endpoints was the
highest tested nominal concentration of 100 µg MPA/L, corre-
sponding to 73 µg/L GMMC. The EC10 for survival of the parental
ﬁsh was 18.9 µg/L GMMC, whereas the EC10 for fecundity and
fertilization success was calculated to be >73 µg MPA/L GMMC
(D. Gilberg and G. Chambers, unpublished data). At the end of
the OECD test guideline 210 (Organisation for Economic Co‐
operation and Development 2013) test phase at 34 d (total
duration of the test 57 d), no concentration–response relationship
was observed for the parameter hatching success (NOEC 73 µg/L,
EC10 >73 µg GMMCMPA/L), but a clear concentration–response
relationship was observed for posthatch success (survival) and
number of healthy ﬁsh, with a NOEC of 10.9 µg MPA/L and an
EC10 of 5.8 µg MPA/L (GMMC; no CI), as well as length of the
surviving F1 ﬁsh, with a NOEC of 1.32 µg/L and an EC10 of 31.9
(CI = 1.3–78) µg MPA/L, and ﬁnally wet weight of the surviving F1
ﬁsh with a NOEC of 1.32 µg/L and an EC10 of 10.6 (CI = 8–14.8)
µg MPA/L (D. Gilberg and G. Chambers, unpublished data). At
the highest tested concentration of 0.1 mg MPA/L nominal con-
centration (73 µg/L GMMC), only 2 of 75 hatched ﬁsh survived
until the end of the test, showing that the test concentration
range was well chosen. The most sensitive endpoints in this
partial life cycle test were survival and growth in terms of length
and mass of the young F1 ﬁsh; the effects were comparatively
small but statistically signiﬁcant at p = 0.05. In contrast, the F0
generation was impacted to a lesser extent. Thus, the overall
NOEC for all endpoints in both F0 and F1 generations was 1.32
µg MPA/L, and the lowest EC10 was 5.8 µg MPA/L, both GMMC.
These relatively low (sub)chronic endpoints in ﬁsh are sup-
ported by Wu et al. (2006), who described a signiﬁcant in-
hibition of angiogenesis of the intersegmental blood vessels of
embryonic D. rerio exposed to MPA concentrations of
≥0.9 µmol/L (288 µg/L) in the short time window of 32 to 48 h
post fertilization (hpf). In view of the rapid embryogenesis of D.
rerio, Gao et al. (2014) exposed dechorionated zebraﬁsh eggs
from 2 to 72 hpf (when morphogenesis is basically complete) to
different concentrations of MPA. As endpoints, heart rate and
rhythm were assessed at 52 hpf, and pericardial edema,
circulation, hemorrhage, and thrombosis were observed at
72 hpf. The MPA exposure resulted in pericardial edema at
6.92 µmol/L (2217 µg/L) and in abnormal body shape, axis
shortening, enlarged yolk sac, and decreased motility at the
lowest tested concentration of 1.38 µmol/L (442 µg/L); with the
concentrations tested in that study, no NOEC was found.
Thus, both Wu et al. (2006) and Gao et al. (2014) support
developmental toxicity of MPA at concentrations <300 µg/L in
short‐term embryotoxicity studies, in agreement with the
partial life cycle test reported in the present study. In addition,
Gao et al. (2014) also exposed D. rerio embryos at 72 hpf in an
acute toxicity assay over 24 h; this test resulted in an LC50 of
55.4 µmol MPA/L (17.75 mg/L), which is clearly lower than the
results reported for juvenile carp over 96 h in an OECD test
guideline 203 (Organisation for Economic Co‐operation
and Development 1993) test of >100 mg/L (European Chem-
icals Agency 2018) and may evidence increased sensitivity of
embryonic stages.
On a broader scale of comparison, developmental toxicity
as observed in D. rerio was also observed in Wistar rat em-
bryos, murine embryonic stem cells, and mouse ﬁbroblasts
exposed to MPA (Eckardt and Stahlmann 2010), and in chicken
embryos (Veselý and Veselá 1991, publication in Czech
language, seen only as the abstract). Thus MPA has been seen
to cause proliferation and cellular and developmental toxicity
to mammalian and avian embryos, stem cells, or ﬁbroblasts
at concentrations of ≥31 µg/L in mammalian systems, in
agreement with the effects seen in ﬁsh.
Sewage treatment and aquatic PNECs
The microorganism PNEC for STPs was derived from the
activated sludge respiration inhibition test according to OECD
test guideline 209 (Organisation for Economic Co‐operation
and Development 2010), which resulted in a 3‐h EC50 of
2213 mg/L and an EC10 of 69 mg/L (European Chemicals
Agency 2018), by applying an assessment factor of 10 to the
EC10, resulting in a PNECSTP of 6900 µg MPA/L. This ﬁnding is
indirectly supported by the only tested concentration of 20 µg
MPA/L in the OECD test guideline 314B (Organisation for
Economic Co‐operation and Development 2008) bio-
degradation study, in which biodegradation began without any
delay or lag phase (T. Junker and M. Herrchen, unpublished
data), and also by a ready biodegradability study with
MPM, which showed no inhibition of activated sludge activity
at a nominal concentration of 100 mg MPM/L (A. Häner,
unpublished data).
The NOEC‐based aquatic PNEC (PNECNOEC) was derived
from the lowest chronic NOEC from the tests with green algae,
cyanobacteria, daphnids, and ﬁsh with an assessment factor of
10, resulting in a PNECNOEC of 0.132 µg MPA/L based on the
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ﬁsh NOEC. The EC10‐based PNECEC10 was derived from the
same tests, resulting in 0.58 µg MPA/L, also based on ﬁsh,
which were the most sensitive species among the 4 groups
tested.
Aquatic environmental risk assessment
For STPs, PECs or MECs were compared with the PNEC STP
by calculating the risk quotient PEC/PNEC. The highest reﬁned
PECSTP was 8.83 µg/L (Table 2), and the highest STP efﬂuent
MEC was 4.19 µg/L (Singer et al. 2016); the PNECSTP based on
OECD test guideline 209 (Organisation for Economic Co‐
operation and Development 2010; FASS 2018) was 6900 µg/L.
Thus, the highest PEC‐based risk quotient for STPs was
0.00128, and the highest MEC‐based risk quotient was 0.0006.
These low risk quotients suggest no signiﬁcant risk for STPs
from the use of MPM and MPA.
Similarly, for receiving freshwaters, the initial EMA PEC was
0.299 µg/L, and the average and median reﬁned PECs, de-
pending on STP removal, were quite close together, with 0.082
and 0.058 µg/L for 12% removal, 0.058 and 0.042 µg/L for
43.6% removal, and 0.037 and 0.027 µg/L for 73.1% removal;
the highest reﬁned PECs per country were 0.532, 0.383, and
0.245 µg/L for the 3 removal rates, respectively. The aquatic
PNECNOEC was 0.132 µg/L, and the PNECEC10 was 0.580 µg/L.
The corresponding risk quotients for the PNECEC10 are shown
in Table 3 (showing the PNECNOEC risk quotient as well would
inﬂate the table even more). Some cases with a risk quotient >1
suggest there may be risk to surface waters. The situation be-
comes even more complex with a distribution of all MECs, of
the population‐weighted reﬁned use‐based PECs for the 24
countries and of the ePiE PECs, the latter including both %ile
distributions and mean‐, low‐, and high‐ﬂow conditions.
Therefore, these risks are shown graphically in Figure 3.
All PECs or MECs with a risk quotient >1 (i.e., >0.132 µg
MPA/L for PNECNOEC or >0.580 µg MPA/L for PNECEC10) signify
potential risk. The initial use‐based Europe‐wide PEC (black
ﬁlled circle in Figure 3A) shows a risk quotient of 2.27 for the
PNECNOEC but no signiﬁcant risk (risk quotient 0.516) for
the PNECEC10. The percent‐ranked reﬁned, total‐MPA‐use‐,
water‐use‐, and dilution‐factor–based PECs per country as-
suming 12% (black triangles pointing down) or 73.1% (black
triangles pointing up) removal in STPs showed no signiﬁcant risk
based on the PNECNOEC for 21 of 24 countries, or >94% of
instances referring to total population, with 3 countries (<6% of
total population) potentially at risk. All the latter 3 countries are
characterized by a combination of above average total MPA
use and below average water use times receiving water
dilution. The average and median reﬁned PECs were 0.082 and
0.088 µg MPA/L, respectively, for low (12%) STP removal,
and the average and median reﬁned PECs were 0.037 and
0.027 µg MPA/L, respectively, for high (73.1%) STP removal.
Hence, for both averages and medians, the PNECNOEC indicates
no signiﬁcant risk. Based on the PNECEC10, none of the
24 countries in both low‐ and high‐removal scenarios show
potential risk.
The mean‐ﬂow ePiE PEC distribution for the Guadalquivir,
Ouse, Rhine, and Turia catchments are shown in Figure 3B, as
thick green, brown, orange, and mauve lines, with the low‐ﬂow
PECs in the same colors to the right and the high‐ﬂow PECs to
the left. All ePiE PEC lines have in common that the graphed
values only start the PECs at ≥0.0005 µg/L, which corresponds
to half the LOQ for the MECs; lower values are not shown. The
mean‐ﬂow ePiE PEC distribution for the Rhine catchment
(orange lines) suggests no signiﬁcant risk for approximately
89% based on the PNECNOEC (left vertical red line, Figure 3B)
and, vice versa, potential risk for approximately 11% of the
whole Rhine catchment; based on the PNECEC10 (right vertical
red line), no signiﬁcant risk is indicated up to approximately
97.5% and a potential risk for approximately 2.5% of the whole
catchment. Under low ﬂow conditions, the percentages at no
risk decreased to approximately 72 and approximately 92%
based on the PNECNOEC and the PNECEC10, respectively. The
mean‐ﬂow ePiE PEC distribution for the Guadalquivir catch-
ment (green lines) suggests no signiﬁcant risk for approximately
78% based on the PNECNOEC and >89% based on the
PNECEC10; for the worst‐case low‐ﬂow Guadalquivir PECs, no
signiﬁcant risk appeared for approximately 68% based on the
PNECNOEC and for approximately 80% based on the PNECEC10.
The lower inclination of the Guadalquivir PECs in comparison
with the Rhine in Figure 3 is likely the result of a higher spatial
variation in concentrations; this can be due to geographical
variation in ﬂow and/or population density (consider the
presence of Cordoba and Seville in this midsize river basin),
plus all the factors that inﬂuence concentrations in a warm
Mediterranean climate zone. For the Turia catchment (mauve
lines) mean ﬂow, no risk emerged for 96.5% for PNECNOEC and
>99% for PNECEC10; for Turia low ﬂow, there was no risk for 90
and 96%, respectively. Lastly, for the Ouse catchment (brown
lines) mean ﬂow, there was no signiﬁcant risk for 91% for
PNECNOEC and >99% for PNECEC10; for Ouse low ﬂow, there
was no risk for 80 and 93%, respectively.
All available MECs were percentage ranked and graphed and
are shown in Figure 3C. Of the total of 110 MECs (bright blue
dots), 51 (46.4%) were below the LOQ. The remaining MECs
increased up to a maximum of 0.656 µg MPA/L. Five of the 110
MECs (4.6%) were above the PNECNOEC of 0.132 µg/L, whereas
only 1 (0.91%) was higher than the PNECEC10 of 0.580 µg/L.
Figure 3 shows ﬁrst that the distribution of the MECs groups
nicely with the ePiE PECs: quantiﬁable (>0.001 µg/L) MECs start at
approximately 50% of the total number of samples, which is not
too far from that of the ePiE PECs. Also, the general inclination
and highest MEC ﬁt quite well into the ePiE PECs. However, this
ﬁt might be an artifact, seeing that the MECs are from Switzerland
(speciﬁcally, a part that does not drain into the Rhine catchment),
Poland (which is not yet incorporated into the ePiE), and north-
eastern Spain (which is not part of the Turia or Guadalquivir
catchments and climatically not the same as southern Spain).
Hence, the ﬁt may represent a genuine property of use, STP
removal, and environmental fate of MPA, but it might be co-
incidence, or somewhere in between. Also, the comparison of the
reﬁned PECs per country, in particular with high (73.1%) STP
removal, may be tricky, because compound MECs from only
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3 countries, with widely varying numbers of measurements, are
being compared with a distribution of 24 single‐country average
PECs. Still, reasonable commonalities are the upper (99th %ile)
ends of all distributions, which range between 0.1 and nearly
10 µg/L and which are certainly dependent on the total amount
of MPA introduced into all models and samples. Also, the
European Union‐wide PECs without removal and with low and
high removal in STPs agree quite well overall with the ePiE
PECs and the MECs, but also with the single‐country PECs
with low and high removal. Although it is recognized that the
comparisons are not straightforward and may be equivocal,
it is proposed that there is sufﬁcient overlap to accept some
commonalities, speciﬁcally in the upper regions of PECs and
MECs, so that a comparison of the PEC and MEC distributions
seems reasonably well founded.
Antibiotic resistance risk assessment
Noto et al. (1969) tested the activity of MPA against various
microorganisms, both fungi and some strains of bacteria. For
12 strains of S. aureus they determined MICs between 31.25
and 125 mg MPA/L; for Staphylococcus epidermidis and 2
strains each of Shigella ﬂexneri, Proteus vulgaris, Escherichia
coli, Pseudomonas aeruginosa, and Salmonella enteritidis, they
found MICs of 125 to >500 mg MPA/L. These high MIC values
characterize MPA as a rather weak antibiotic. Higher inhibition
of MPA was shown against pathogenic fungi of the genera
Candida, Willia, Cryptococcus, Microsporum, Aspergillus, and
Trichophyton, with MICs ranging from 3.9 to 500 mg/L (Noto
et al. 1969). Based on the 23 bacterial MICs given by Noto
et al. (1969), a provisional PNECABR for MPA can be derived
following Kümmerer and Henninger (2003) by dividing the
lowest MIC by 100, resulting in a ﬁrst PNECABR of 312.5 µg/L.
The procedure described by Bengtsson‐Palme and Larsson
(2016) results in a second provisional PNECABR for MPA, cal-
culated by J. Bengtsson‐Palme, of “76 µg/L (which would be
rounded down to 64 µg/L”; J. Bengtsson‐Palme, personal
communication to J.O. Straub, 25 July 2018). Selecting the
lower of the 2 values results in a provisional PNECABR of 64 µg
MPA/L, based on a small MIC dataset.
This provisional PNECABR of 64 µg MPA/L can now be
compared with the PECs for STPs and surface water and with
the highest MECs available. The highest use‐based reﬁned
PECSTP was 8.83 µg MPA/L (Table 2), whereas the highest STP
efﬂuent MEC was 4.19 µg/L (Singer et al. 2016); the corre-
sponding risk quotients were 0.138 and 0.065, respectively,
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TABLE 3: Surface water risk quotients for predicted no‐effect concentration based on 10% effect concentration (PNECEC10; 0.58 µg mycophenolic
acid [MPA]/L)
Surface freshwaters risk quotients, based on STP removal of
PECs or MECs 0% 12% 43.6% 73.1% NA
Average initial EMA EU PEC 0.516
Average reﬁned PEC per country 0.141 0.100 0.064
Median reﬁned PEC per country 0.100 0.072 0.047
Highest reﬁned PEC per country 0.917 0.660 0.422
Lowest reﬁned PEC per country 0.003 0.002 <0.002
Rhine catchment mean ﬂow median ePiE PEC 0.102
Rhine catchment mean ﬂow 99th percentile ePiE PEC 1.157
Rhine catchment mean ﬂow 1st percentile ePiE PEC <0.002
Rhine catchment low ﬂow median ePiE PEC 0.036
Rhine catchment low ﬂow 99th percentile ePiE PEC 4.597
Ouse catchment mean ﬂow median ePiE PEC 0.083
Ouse catchment mean ﬂow 99th percentile ePiE PEC 1.226
Ouse catchment mean ﬂow 1st percentile ePiE PEC 0.002
Ouse catchment low ﬂow median ePiE PEC 0.336
Ouse catchment low ﬂow 99th percentile ePiE PEC 4.967
Turia catchment mean ﬂow median ePiE PEC 0.048
Turia catchment mean ﬂow 99th percentile ePiE PEC 0.955
Turia catchment mean ﬂow 1st percentile ePiE PEC <0.002
Turia catchment low ﬂow median ePiE PEC 0.300
Turia catchment low ﬂow 99th percentile ePiE PEC 7.922
Guadalquivir catchment mean ﬂow median ePiE PEC <0.002
Guadalquivir catchment mean ﬂow 99th percentile ePiE PEC 9.474
Guadalquivir catchment mean ﬂow 1st percentile ePiE PEC <0.002
Guadalquivir catchment low ﬂow median ePiE PEC <0.002
Guadalquivir catchment low ﬂow 99th percentile ePiE PEC 21.41
Maximum MEC 1.131
Realistic worst‐case (90th percentile) MEC 0.983
Median MEC ~0.003
EMA EU PEC =MPA PEC based on overall European amounts of MPA and mycophenolate mofetil (MPM), no human metabolism beyond hydrolysis of MPM to MPA and
no STP removal included, default dilution factor of 10 (European Medicines Agency 2015); ePiE PEC = geographical information system–based surface water PEC
according to Oldenkamp et al. (2018); MEC =maximum, 90th percentile and median of 110 available surface water measured environmental concentrations (MECs) from
Switzerland, Spain, and Poland (based on Rossi and Cheseaux 2013; Franquet‐Griell et al. 2016, 2017c; Giebułtowicz and Nałec̨z‐Jawecki 2016); PEC = predicted
environmental concentration; MPM = mycophenolate mofetil; STP = sewage treatment plant; NA = no data available.
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suggesting no signiﬁcant antibiotic resistance risk for STPs. For
surface waters, all PECs including the highest, the Guadalquivir
River low‐ﬂow 99th %ile ePiE PEC, were below the PNECABR,
and thus all risk quotients were ≤0.194, all reﬁned PEC‐per‐
country risk quotients were ≤0.0083, and all mean‐ and low‐
ﬂow median ePiE PEC risk quotients were ≤0.00033; ﬁnally, the
highest MEC risk quotient was 0.0103. Both models and
measurements imply that throughout Europe, even in the









FIGURE 3: Risk graphs based on predicted environmental concentration (PEC) and measured environmental concentration (MEC) for mycophe-
nolic acid (MPA). (A) PECs. Filled black circle = use‐based initial European Union PEC without removal in sewage treatment plants (= initial
European Medicines Agency PEC); half‐ﬁlled circle = European Union PEC with 12% removal; open circle = European Union PEC with 73.1%
removal. (B) Exposure to pharmaceuticals in the environment (ePiE) PEC distributions, assuming 12% removal in sewage treatment plants. Fat
mauve line = Turia catchment mean‐ﬂow PEC; ﬁne mauve lines = Turia catchment high‐ﬂow (to left of mean) and low‐ﬂow (to right of mean) PECs.
Same for brown lines = Ouse catchment; orange lines = Rhine catchment; green lines = Guadalquivir catchment. The PECs were cut off at <0.0005
µg/L. (C) MECs. Percent‐ranked distribution of 110 MPA MECs from Switzerland, Spain, and Poland; nondetects (limit of quantitation = 0.001 µg/L)
increase the rank of the lowest shown detected MEC. In all panels, no‐observed‐effect concentration (NOEC)‐derived (0.132 µg/L, left)
and 10% effect concentration (EC10)‐derived (0.580 µg/L, right) predicted no‐effect concentrations (PNECs) are shown as vertical red lines. Symbols
to the left of the PNECNOEC or PNECEC10 show no signiﬁcant risk for the respective PNEC, and symbols to the right show potential risk.
EU = European Union.
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worst‐case scenario of a southern Mediterranean catchment
with extremely low river ﬂow in summer, no signiﬁcant anti-
biotic resistance risk emerges for MPA.
Secondary poisoning for (semi)aquatic top
predators and humans
Risk assessments for secondary poisoning of both (semi)
aquatic top predators and human consumers of water and ﬁsh
depend on mammalian toxicity data. Co‐author T. Pﬁster col-
lated and assessed such data for the derivation of an ADE value
for MPA (T. Pﬁster, unpublished data). According to these same
data, based on chronic and subchronic studies with mice, rats,
dogs, and monkeys, adverse effects on the hematopoietic and
lymphoid system were identiﬁed as the leading changes; the rat
was the most sensitive species, and the no‐observed‐adverse‐
effect level (NOAEL) after chronic (6 or 12 mo) oral treatment
was established at 2 mg/kg body weight/d. The anticipated
therapeutic effect, immunosuppression, was achieved at or
below no‐effect dose levels for toxicity in (sub)chronic studies in
rat and monkey, as assessed in vitro by the effect of serum from
dosed animals. In terms of genotoxicity, MPM did not induce
point mutations or primary DNA damage in the presence or
absence of metabolic activation. More recent studies with ex-
tended exposure conditions have shown that MPM possesses a
clastogenic potential, which becomes expressed only at highly
cytotoxic dose levels, apparently as a consequence of purine
synthesis inhibition. It was not carcinogenic in mice dosed orally
for 104 wk at 25, 75, or 180 mg/kg body weight/d, or in rats
dosed for at least 104 wk at 3, 7, or 15 mg/kg body weight/d. On
the contrary, in secondary pharmacology studies (T. Pﬁster, un-
published data), MPM demonstrated in vitro antitumour effects
in lymphocyte and erythrocyte systems, and MPM prolonged
survival times in mice with large cell lymphoma. In a female
fertility and reproduction study in rats dosed orally, the highest
dose of 4.5 mg/kg body weight/d caused malformations (mainly
of the head and eyes) in the pups in the absence of maternal
toxicity, whereas there was no effect on fertility; the NOAEL was
1.5 mg/kg body weight/d. In teratology studies, rats and rabbits
were dosed orally daily, resulting in deformities including head
and ventral wall abnormalities in the rat and cardiovascular,
kidney, and lung effects in the rabbit; the no‐observed‐
effect level (NOEL) for teratogenic changes was 2 mg/kg body
weight/d for rats and 30 mg/kg body weight/d for rabbits
(T. Pﬁster, unpublished data).
The ADE was derived based on the available nonclinical
and clinical data, with the critical effects identiﬁed as 1)
immunosuppression and secondary effects thereof and 2)
teratogenicity; in addition, the relevance of positive results in
genotoxicity tests was assessed (T. Pﬁster, unpublished data).
Based on the NOAEL of 2 mg/kg body weight/d in the 12‐mo
oral toxicity study in the rat, an ADE was derived by multi-
plying this NOAEL by a default body weight of 60 kg for hu-
mans and dividing by adjustment factors, namely, 6.2 for
extrapolation from rats to humans, 10 for variability between
individuals, 1 for study duration of 1 yr for rodents, 5 for se-
verity of systemic toxicity (hematopoiesis, immunotoxicity),
and 3 for use of an established NOAEL instead of an NOEL;
this derivation results in a ﬁrst ADE of 0.1 mg MPM/60‐kg
person/d. Based on the NOEL of 2 mg/kg body weight/d in
the teratogenicity study in the rat, an ADE was derived by
multiplying this NOEL by a default body weight of 60 kg for
humans and dividing by adjustment factors, namely, 6.2 for
extrapolation from rats to humans, 10 for variability between
individuals, 1 for reproductive studies in which the whole
period of organogenesis was covered, 10 for a teratogenic
effect without maternal toxicity, and 1 for use of an estab-
lished NOEL; this derivation resulted in a second ADE of 0.19
mg MPM/60‐kg person/d (T. Pﬁster, unpublished data). The
weak clastogenic potential observed at higher doses was
considered to be irrelevant at these exposure levels. Because
the ﬁrst ADE was lower than, and therefore also protective of,
the second, 0.1 mg MPM/60‐kg person/d was selected as the
ADE. Stoichiometrically, this ADE for MPM corresponds to
0.0739 mg MPA/d, which was rounded to 0.075 mg or 75 µg
MPA/d. The MTDI for an otter was derived by normalizing the
ADE for a 60‐kg human to the otter with a default body mass
of 10 kg, resulting in an MTDI of 0.0125 mg or 12.5 µg MPA/
10‐kg otter/d.
For the top predator risk assessment through secondary poi-
soning, an otter is assumed to consume 1 kg of ﬁsh plus 0.79 L
water every day (European Commission 2011; Murray‐Smith et al.
2012). The ﬁsh will take up MPA from the water with the highest
modeled BCF, the geometric average of the SciFinder values in
the pH range of 5 to 9, of 6.22 (see the previous section, Phys-
icochemical properties and environmental fate). Using the Rhine
River mean‐ﬂow 99th %ile ePiE PEC of 0.671 µg/L, which is close
to the highest MEC available of 0.656 µg/L, and the BCF of 6.22,
results in 4.17 µg MPA/kg ﬁsh. In addition, the otter drinks 0.79 L
of water at 0.671 µg MPA/L or 0.53 µg MPA/d. Thus, the total
MPA uptake for an otter is 4.7 µg MPA/d. This is below the MTDI
of 12.5 µg MPA/d, with a risk quotient of 0.376. Using the Rhine
River low‐ﬂow 99th %ile ePiE PEC, in contrast, results in a risk
quotient of 43.2, suggesting potential risk. As worst‐case sce-
narios, the highest Guadalquivir River mean‐ and low‐ﬂow 99th %
ile ePiE PECs result in risk quotients of 88.9 and 201, respectively.
These risk quotients suggest potential risk in extreme exposure
scenarios to top predators like otters, which are reported to occur
in the whole of Europe including the Iberian Peninsula and the
Guadalquivir catchment (International Union for Conservation of
Nature 2019). As for the aquatic risk assessment, the high ends of
the ePiE PEC distributions signal potential risk, whereas the
median reﬁned and ePiE PECs suggest no signiﬁcant risk.
For the human secondary poisoning risk assessment, a de-
fault 60‐kg person is expected to consume 2 L of drinking
water/d (European Commission 2011; Murray‐Smith et al.
2012). Assuming as a worst case that no elimination of MPA
takes place during drinking water treatment (despite the
evidence to the contrary cited previously), this corresponds to
1.312 µg MPA/d. Using the data calculated just above for the
otter, an amount of 115 g ﬁsh meat is predicted to contain
0.480 µg MPA. Therefore, a human is expected to consume a
total of 1.792 µg MPA/d through secondary poisoning, which is
well below the ADE of 75 µg/d, with a risk quotient of 0.024.
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For human secondary poisoning, even the extreme Gua-
dalquivir River low‐ﬂow 99th %ile ePiE PEC of 12.419 µg MPA/L
does not result in a signiﬁcant risk, with a risk quotient of 0.442.
Hence, there is no signiﬁcant risk for human secondary poi-
soning.
Persistence, bioaccumulation, and toxicity
assessment
The water/sediment test (Z. Yan, unpublished data), the OECD
test guideline 314B (Organisation for Economic Co‐operation
and Development 2008) biodegradation test (T. Junker and
M. Herrchen, unpublished data), and the kbiodeg results from
Franquet‐Griell et al. (2017a) suggest that MPA is not persistent.
Furthermore, measured log DOW values of 2.28 at pH 5, 0.48 at
pH 7, and ≤–1.54 at pH 9 (V. Nicholson et al., unpublished data)
suggest that MPA is not bioaccumulative, which is supported by
modeled BCFs (US Environmental Protection Agency 2016;
American Chemical Society 2018). Lastly, MPA is toxic based on
mammalian carcinogenic, mutagenic, or reprotoxic properties
(T. Pﬁster, unpublished data) and on chronic ecotoxicity in green
algae and ﬁsh with NOECs <10 µg/L (European Chemicals
Agency 2018; D. Gilberg and G. Chambers, unpublished data).
Overall, even though it is toxic, MPA is not classiﬁed as persistent,
bioaccumulative, or of speciﬁcally high ecotoxicity.
DISCUSSION
Once taken up, MPA is mainly metabolized by conjugation
to the inactive glucuronide MPAG and basically excreted
without further metabolism, with a terminal half‐life of approx-
imately 18 h; less than 1% of MPA is phase‐I‐metabolized to 6‐O‐
desmethyl‐MPA (Wishart et al. 2018; Royal Pharmaceutical So-
ciety 2018). Glucuronides are cleft in STPs (Möhle and Metzger
2001), resulting in free MPA. It was shown in the OECD test
guideline 314B (Organisation for Economic Co‐operation and
Development 2008) test that [14C]‐MPA was biodegradable in
aerobic activated sludge (T. Junker andM. Herrchen, unpublished
data), conﬁrming the ﬁnding by Franquet‐Griell et al. (2017a). The
biodegradation reaction constant kbiodeg from the new OECD test
guideline 314B (Organisation for Economic Co‐operation and
Development 2008) test was entered into SimpleTreat 4.0, which
calculates a removal of 12% for a standard STP with primary
sludge settler, aeration basin, and a ﬁnal settling tank, without
nitriﬁcation/denitriﬁcation or further treatment. However, Fran-
quet‐Griell et al. (2017a) showed in their sequencing batch reactor
that the kbiodeg for MPA increases with every cycle of their reactor;
their maximum kbiodeg in the ﬁfth cycle results in a SimpleTreat
removal of 73%. Because repeat exposure is certain for an API
with daily administration over a lifetime, the PECs derived using
12% removal, including the ePiE PECs, constitute worst‐case as-
sumptions.
These PECs and the few MECs are compared with PNECs
derived from chronic effects in green algae, cyanobacteria,
daphnids, and ﬁsh. Daphnia show the least sensitivity to MPA,
whereas the blue—green Anabaena are approximately 8 times,
green algae 70 times, and ﬁsh nearly 500 times more sensitive
than daphnids. The strong effect on ﬁsh is primarily manifested
in posthatch survival and growth parameters (length, body
weight) of the fry, but not in survival of the parental generation,
nor in fecundity, fertilization, hatchability, or obvious malfor-
mations (D. Gilberg and G. Chambers, unpublished data). The
relatively nonspeciﬁc endpoints responsible for the NOEC and
EC10 may indicate an increased general stress for the ﬁsh,
potentially caused by the pharmacological mode of action,
immune inhibition. The ﬁnding that cyanobacteria are less
sensitive to MPA (D. Gilberg and G. Chambers, unpublished
data) than green algae (European Chemicals Agency 2018) may
ﬁrst of all conﬁrm that MPA is a rather weak antibiotic. The
green algae were pre‐exposed to MPA in the dark for 24 h
before the actual 72‐h testing period under illumination
started, meaning that the total exposure duration was 96 h, in
contrast to the cyanobacteria exposure, which totaled 72 h
(European Chemicals Agency 2018). Also, as noted in the In-
troduction, IMDPH inhibition may be lower in prokaryotes than
in eukaryotes (Digits and Hedstrom 1999; Gunnarsson et al.,
2008), but this might be contradicted by the even lower
sensitivity of the daphnids. Otherwise, the observed 9‐fold
difference in sensitivity between green algae and cyanobac-
teria remains unexplained. Lastly, the daphnids had the least
sensitivity to MPA, with the lowest NOEC of 630 µg/L GMMC
for the endpoints reproduction/fecundity and length of pa-
rental daphnids, whereas for mortality/immobility of parental
daphnids and intrinsic rate of population increase, the NOEC
was 7530 µg/L GMMC, the highest tested concentration in this
assay; the only EC10 that could be calculated was for the
endpoint reproduction/fecundity, namely, 929 µg/L (Egeler
and Chambers 2018). This ﬁnding suggests that parameters
linked to overall ﬁtness were impacted ﬁrst (reproduction
and fecundity plus length [size and growth] of the parental
daphnids) before parameters evidencing overt toxicity
(mortality/immobilization) and population growth (intrinsic rate)
were affected. As for ﬁsh, this may indicate an increased
general stress for the daphnids, potentially caused by the
pharmacological mode of action. Immune inhibition due to
MPA will be investigated, and its sensitivity compared with that
of the standard chronic ecotoxicity endpoints for daphnids and
ﬁsh, in a separate study.
The present environmental risk assessment derives PNECs
from both chronic NOEC and EC10 values. Both are approx-
imations of a true no‐effect concentration (NEC), which would
ideally be used for PNEC derivation. Both NOEC and EC10
values have their biological or statistical advantages and
shortcomings, depending on a clear concentration–response
relationship and the shape and slope of the concen-
tration–response curve, or on statistics applied, as discussed
extensively (e.g., Kooijman 1981; van der Hoeven et al. 1997;
Organisation for Economic Co‐operation and Development
2003), but both are in use. The NOEC has an additional un-
certainty that depends on the spacing factor between the test
concentrations (in addition to the actual biological effect), be-
cause the actual NEC may be precisely at, or nearly one
spacing factor below, the determined NOEC. As a further
shortcoming, the NOEC depends on just one concentration,
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even if data for higher test concentrations are available. In
contrast, in a series with clear concentration–response effects,
the EC10 integrates information from other test concentrations
as well. Because there is a clear dose–response relationship
with relatively steep curves in the ecotoxicity tests with MPA,
the PNEC derivation from the EC10 values is given preference
in the present study. Using the EC10 for the PNEC in human
pharmaceutical environmental risk assessment is not only ac-
cepted but is actually preferred in the recent EMA (European
Medicines Agency 2018) draft guideline. This does not mean,
however, that an EC10 is always higher (i.e., a less sensitive
endpoint) than a NOEC. Speciﬁcally for the abbreviated life
cycle test with MPA reported in the present study, the lowest
NOECs for single endpoints are 1.32 µg/L for both length and
wet weight of the surviving F1 ﬁsh and 10.9 µg/L for posthatch
survival and externally healthy ﬁsh; in contrast, the EC10 values
are 31.9 µg/L for length and 10.6 µg/L for weight, but 5.8 µg/L
for posthatch survival and health (D. Gilberg and G. Chambers,
unpublished data).
The mean‐ and low‐ﬂow 99th %ile ePiE PECs for the Rhine,
Guadalquivir, Turia, and Ouse catchments, but also the 5
highest MECs retrieved, show potential risk for one or both of
the PNECs. On the “safe” side, both the average and median
reﬁned PECs per country as well as the mean‐ﬂow median and
75th %ile ePiE PECs for the Guadalquivir, Ouse, Rhine, and
Turia catchments, but also the median and the 90th %ile of the
surface water MECs show risk quotients of <1. The value of
ePiE as a predictive instrument appears in these different
catchments and scenarios. Instead of simplistic “one‐value”
estimates, ePiE models different seasonal ﬂow rates, different
climate inﬂuences, different population densities, and different
STP treatments. This results in complicated but, based on the
limited comparison with MECs, quite reasonable distributions
that can be used for worst‐ and average‐case assessment of
risks (Table 3 and Figure 3C). In addition, ePiE can be used on a
much ﬁner spatial resolution than whole‐river catchments,
which allows researchers to pinpoint hot spots, stretches, and
regions that show higher concentrations and potential risk than
others and thereby, for instance, to identify STPs that would
proﬁt most from upgrading. Deciding which STPs will be ret-
roﬁtted is a highly political task and clearly beyond this risk
assessment. However, solutions must be sought that do not
just penalize the downstream STP that causes the combined
PEC to exceed the PNEC while all upstream STPs (which con-
tribute to the overall PEC) need not upgrade (or share in the
costs) at all. A fair distribution of upgrading and ﬁnancing even
across state borders may become necessary.
Obviously, a risk characterization for MPA in European sur-
face waters cannot be a simplistic “risk” or “no risk” conclusion,
but will need differentiated discussion. Figure 3 is intended to
support this evaluation by allowing one to derive percentage
ﬁgures for potential risk versus no signiﬁcant risk for the dif-
ferent PEC and MEC scenarios. Thus, the resulting aquatic
environmental risk assessment for MPA in Europe describes a
complex situation in which in the current deterministic risk
scenarios some risk quotients are >1 (<6% of all reﬁned PECs
and MECs) whereas the majority by far (>94% of reﬁned‐
PEC–based and >95% of MEC‐based risk quotients) shows no
signiﬁcant risk. For the ePiE PEC distributions, in view of its
inherently distributional concept, the environmental risk as-
sessment is even more varied because it includes 4 different
catchments with high, median, and low river ﬂow scenarios,
and the results are presented as a distribution from the 1st to
the 99th %iles (Figure 3). Also, the comparable results for the
aquatic top predators support the use of a differentiated en-
vironmental risk assessment. The following questions arise from
these results: “What does’ signiﬁcant risk’ or ’no signiﬁcant risk’
mean?,” “Must a risk quotient <1 apply in all instances exam-
ined?,” or, vice versa, “What percentage of risk quotient >1 are
we willing to accept?” These are partly scientiﬁc but also so-
cietal and political questions; a rational discussion with scien-
tiﬁc input is clearly needed.
The concepts developed in probabilistic environmental risk
assessment (e.g., Campbell et al. 1999; Hart 2001) could pos-
sibly help. Probabilistic environmental risk assessment recog-
nizes that both (eco)toxicity and environmental exposure
cannot be reduced to one single value each. Predictions (or
measures) of both effects and exposures are just parts of dis-
tributions. Comparing these distributions elucidates where
they overlap—this intersection outlines the area of potential
risk. Also, the overlap allows a quantiﬁcation, in terms of both
share of species and share of environmental concentrations at
risk (e.g., Straub 2008). Moreover, the goal of environmental
risk assessment is generally not considered one that would
protect every single individual organism, in contrast to human
health risk assessment. For environmental risk assessment, the
main objective is the protection of ecosystem functions and
basic structure. This means that, within limits and with due
consideration, a certain amount of risk may be tolerated as long
as the ecosystem as a whole continues to function, for example,
by organisms taking over the functions of other organisms, by
replenishment of impaired organisms through immigration, by
the development of resilience, or through a limited spatial
extent of risk. The present environmental risk assessment,
which is distributional (in the geographical sense) for the PECs
and MECs, but deterministic for the ecotoxicity, shows quan-
tiﬁable overlap on the exposure side. How much overlap or
percentages at risk can be tolerated must be informed by sci-
ence, mainly ﬁeld ecology but also ecotoxicology. However,
other considerations need to be integrated as well, for ex-
ample, the usefulness and necessity of the API, existing alter-
natives, and the value that society accords to ecosystems and
human health, but also the possibility and cost of risk reduction
measures. Again, scientiﬁc, societal, and political questions
must be addressed.
When these results are judged, it should be kept in mind
that uncertainty is an inherent property of risk assessment
(Wilson and Crouch 1987; Suter 1990; Darbra et al. 2008) and
that such uncertainty applies to PECs, MECs, PNECs, and the
resulting risk quotients. Although the reﬁned and ePiE PEC
distributions per country are comparable, this may primarily
reﬂect a basic similarity in the procedures of generating PECs,
in addition to (hopefully) a good measure of realism in the
algorithms. Also, the MEC distributions may be strongly
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skewed, because the MEC data are scarce (only 3 countries [or
regions] and a high variation in numbers of MECs/country), so
the seemingly comparable picture for the MECs may or may
not be an artifact. However, all distributions do have in
common the result that the general distributions of ePiE PECs
and the MECs are similar and, in particular, that some, a limited
percentage, of the different PECs and MECs are higher than
the PNECs. How much higher exactly depends on the data
behind the distributions—a further uncertainty. Also, the
PNECs, whether derived from NOEC or EC10 values, are not
“certain.” Small deviations between tests using the same or-
ganisms and substances in different laboratories are common
and only to be expected in view of stochasticity in biological
(and environmental fate) processes (e.g., Hamda et al. 2014;
Wender et al. 2018). In addition, although an assessment factor
of 10 is commonly used for chronic PNEC derivation, this factor
could potentially be higher or lower, depending on properties
of the test substance in question, speciﬁcally on the depth of
knowledge of its mode of action and the presence or absence
of the respective biological receptors in the different organism
groups. Hence, even the ﬁgure of <6% at risk (see just above)
must be taken with a good measure of scepticism—the fraction
at risk could be higher or lower.
Last but not least, the dearth or absence of feasible
alternatives to MPM/MPA for immune‐challenged patients
must be addressed as well. Only a limited number of tested
immunosuppressive APIs is available for solid‐organ transplant
patients, or, off‐label, for certain autoimmune diseases. Taylor
et al. (2005) and the World Health Organization (2019) list several
small‐molecule alternatives to MPA for solid‐organ transplant
patients, in addition to the more recent biologics (poly‐ or mon-
oclonal antibodies) that all need to be administered intravenously.
However, these small molecules cannot be used or exchanged
indiscriminately due to different use, metabolism, and adverse
effects proﬁles (Taylor et al. 2005; Straub 2016). Hence, restricting
proven, efﬁcacious APIs is available for these patient groups
might have extremely serious consequences. Thus, patient ben-
eﬁt and the dearth of alternative APIs may be in opposition to
environmental safety in a number of cases. How can this contra-
diction be resolved? It may boil down to the question, “What can
be done to minimize MPA concentrations in the environment?”
We are well aware that the following considerations clearly go
beyond pure risk assessment, but we still want to list some ideas.
Risk reduction measures aimed at lowering PECs are scarce for
human medicines, speciﬁcally for APIs like MPM/MPA for which
noncompliance is not an issue. In such cases, providing or up-
grading to the best available technology in STPs will certainly play
a highly important role (e.g., Abegglen and Siegrist, 2012; Björ-
lenius and Breitholz 2016), in particular with a substance that
basically is biodegradable like MPA. The situation may be
somewhat different in cases in which alternative APIs with the
same therapeutic function exist, but even in such cases sub-
stitution should be applied with caution (Straub 2016). In addition,
in view of the limited oral bioavailability of MPA itself, the ad-
ministration of the prodrug MPM could ensure active concen-
trations of MPA in the patients at lower overall dosages, thanks to
the higher bioavailability of MPM; this would consequently
decrease the amount of MPA excreted into wastewaters and ul-
timately into the environment (Straub 2016). Both are potential
measures to reduce the worst‐case concentrations of MPA in the
environment, without denying a potentially life‐saving medicine
to anyone. As maintained by patient organizations, the pharma-
ceutical industry, and the European Commission (2019), patient
access to medicines must not be compromised.
CONCLUSIONS
Both MPA and its prodrug MPM are excreted as MPA and its
glucuronide. In STPs, 12 to 73.1% of total MPA will be bio-
degraded, whereas adsorption to sludge (with subsequent
transfer to soil) is negligible. In the receiving waters, further
photo‐ and biodegradation are expected to be important fate
processes for MPA. Therefore, the PECs depend mainly on actual
use of MPM plus MPA in different countries, on per capita water
use, on removal in STPs, on average dilution of the STP efﬂuents
in the different states, and on further degradation in the receiving
waters. The present study suggests that PEC models of different
complexities correspond reasonably well with each other and with
the few MECs retrieved. Comparing in particular ePiE PECs with
the PNECs results in a risk assessment that is not a trivial “risk” or
“no risk” conclusion. For the majority of situations, no signiﬁcant
risk appears, but in a minor fraction there is potential risk with
1< risk quotient< 10. However, ePiE also identiﬁes river stretches
with increased concentrations that are potentially at risk, high-
lighting point sources (STPs) that might proﬁt from upgrading.
Therefore, ePiE emerges as a potent instrument for geo-
graphically detailed PEC derivation and environmental risk
assessment, and as a guide for risk management, in particular
when additional catchments, ideally all through Europe, are in-
tegrated. On another level, this differentiated environmental risk
assessment of MPA in surface waters calls for a rational, science‐
based, societal and political discussion of what kind and
what percentage of risk to the environment society is willing or
not willing to accept—and conversely, what kind of risk man-
agement measures society is willing to impose or install, partic-
ularly in the light of unhindered patient access to a life‐saving
medicine.
Supplemental Data—The Supplemental Data are available on
the Wiley Online Library at DOI: 10.1002/etc.4524.
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